Richard Law
Stock Analyst at Goldman Sachs
(0.19)
# 4,388
Out of 5,055 analysts
68
Total ratings
25%
Success rate
-19.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Richard Law
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Neutral | $19 → $29 | $25.00 | +16.00% | 2 | Oct 30, 2025 | |
| CRNX Crinetics Pharmaceuticals | Maintains: Neutral | $35 → $40 | $42.67 | -6.26% | 1 | Sep 26, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Buy | $32 → $52 | $40.85 | +27.29% | 7 | Sep 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $27 → $30 | $28.77 | +4.28% | 4 | Aug 7, 2025 | |
| MLTX MoonLake Immunotherapeutics | Maintains: Buy | $74 → $82 | $12.77 | +542.13% | 4 | Aug 6, 2025 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $20 → $18 | $8.41 | +114.03% | 5 | May 14, 2025 | |
| SLN Silence Therapeutics | Maintains: Sell | $4 → $3 | $6.83 | -56.08% | 3 | May 9, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Neutral | $15 → $13 | $3.05 | +326.23% | 3 | May 9, 2025 | |
| CLDX Celldex Therapeutics | Maintains: Neutral | $36 → $31 | $25.55 | +21.33% | 3 | May 9, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $30 | $39.11 | -23.29% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $73 | $96.01 | -23.97% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $11 | $14.37 | -23.45% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $46 → $47 | $21.72 | +116.39% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $63 | $52.53 | +19.93% | 6 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $37 | $64.94 | -43.02% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $76 | $8.70 | +773.56% | 6 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $14 | $2.60 | +438.46% | 3 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $61 | $10.57 | +477.11% | 4 | May 8, 2023 |
Arcutis Biotherapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $19 → $29
Current: $25.00
Upside: +16.00%
Crinetics Pharmaceuticals
Sep 26, 2025
Maintains: Neutral
Price Target: $35 → $40
Current: $42.67
Upside: -6.26%
Mineralys Therapeutics
Sep 9, 2025
Maintains: Buy
Price Target: $32 → $52
Current: $40.85
Upside: +27.29%
Viridian Therapeutics
Aug 7, 2025
Maintains: Buy
Price Target: $27 → $30
Current: $28.77
Upside: +4.28%
MoonLake Immunotherapeutics
Aug 6, 2025
Maintains: Buy
Price Target: $74 → $82
Current: $12.77
Upside: +542.13%
Olema Pharmaceuticals
May 14, 2025
Maintains: Buy
Price Target: $20 → $18
Current: $8.41
Upside: +114.03%
Silence Therapeutics
May 9, 2025
Maintains: Sell
Price Target: $4 → $3
Current: $6.83
Upside: -56.08%
Rocket Pharmaceuticals
May 9, 2025
Maintains: Neutral
Price Target: $15 → $13
Current: $3.05
Upside: +326.23%
Celldex Therapeutics
May 9, 2025
Maintains: Neutral
Price Target: $36 → $31
Current: $25.55
Upside: +21.33%
Viking Therapeutics
Apr 8, 2025
Initiates: Neutral
Price Target: $30
Current: $39.11
Upside: -23.29%
Nov 21, 2024
Initiates: Buy
Price Target: $73
Current: $96.01
Upside: -23.97%
Aug 11, 2023
Reiterates: Neutral
Price Target: $11
Current: $14.37
Upside: -23.45%
Aug 9, 2023
Maintains: Neutral
Price Target: $46 → $47
Current: $21.72
Upside: +116.39%
Aug 8, 2023
Maintains: Neutral
Price Target: $62 → $63
Current: $52.53
Upside: +19.93%
Aug 4, 2023
Maintains: Neutral
Price Target: $36 → $37
Current: $64.94
Upside: -43.02%
Jun 13, 2023
Reiterates: Outperform
Price Target: $76
Current: $8.70
Upside: +773.56%
May 8, 2023
Maintains: Neutral
Price Target: $15 → $14
Current: $2.60
Upside: +438.46%
May 8, 2023
Reiterates: Outperform
Price Target: $61
Current: $10.57
Upside: +477.11%